Catalogo dei prodotti della ricerca

PEPE, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 719
EU - Europa 497
AS - Asia 300
SA - Sud America 18
AF - Africa 15
OC - Oceania 3
Totale 1.552
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 704
IT - Italia 281
SG - Singapore 124
CN - Cina 78
SE - Svezia 47
DE - Germania 39
IN - India 37
GB - Regno Unito 28
TH - Thailandia 24
BG - Bulgaria 18
BE - Belgio 12
CA - Canada 12
NL - Olanda 11
RO - Romania 11
BR - Brasile 10
FI - Finlandia 10
TG - Togo 9
AR - Argentina 8
JP - Giappone 8
PL - Polonia 7
TR - Turchia 6
RU - Federazione Russa 5
AL - Albania 4
ES - Italia 4
FR - Francia 4
HK - Hong Kong 4
AU - Australia 3
DK - Danimarca 3
ID - Indonesia 3
PK - Pakistan 3
TW - Taiwan 3
UA - Ucraina 3
CH - Svizzera 2
CZ - Repubblica Ceca 2
EG - Egitto 2
ET - Etiopia 2
IE - Irlanda 2
IL - Israele 2
LK - Sri Lanka 2
MK - Macedonia 2
MX - Messico 2
PH - Filippine 2
ZA - Sudafrica 2
AM - Armenia 1
AT - Austria 1
BD - Bangladesh 1
HU - Ungheria 1
KR - Corea 1
PA - Panama 1
UZ - Uzbekistan 1
Totale 1.552
Salva come PNG Salva come JPEG
Città #
Rome 120
Singapore 101
Chandler 73
Fairfield 61
Santa Clara 49
Ann Arbor 36
Ashburn 33
Woodbridge 28
Houston 27
Seattle 27
Bangkok 24
Princeton 24
Cambridge 21
Peachtree Corners 21
Milan 20
Sofia 18
Frankfurt am Main 16
Beijing 15
Millbury 14
New York 14
Wilmington 13
Brussels 12
Reston 10
Lomé 9
Staten Island 9
Boston 8
Bremen 8
San Diego 7
Andover 6
Bologna 6
Chicago 6
Florence 6
Lawrence 6
Toronto 6
New Delhi 5
San Paolo di Civitate 5
Berlin 4
Cagliari 4
Delft 4
Helsinki 4
Istanbul 4
Plano 4
Rosario 4
Serra Riccò 4
São Paulo 4
Tirana 4
Tokyo 4
Amsterdam 3
Arezzo 3
Brentwood 3
Buenos Aires 3
Craigavon 3
Dearborn 3
Des Moines 3
Edinburgh 3
Fulham 3
Guangzhou 3
Hefei 3
Hong Kong 3
Jakarta 3
Karachi 3
Lappeenranta 3
London 3
Mentana 3
Naples 3
Norwalk 3
Phoenix 3
Springfield 3
Swansea 3
Täby 3
Vantaa 3
Adelaide 2
Ashquelon 2
Brescia 2
Collegeville 2
Colombo 2
Conroe 2
Dublin 2
Gonder 2
Groningen 2
Hamburg 2
Iasi 2
Los Angeles 2
Madrid 2
Mexico City 2
Minneapolis 2
Modena 2
Montreal 2
Monza 2
Nanjing 2
Osaka 2
Ottawa 2
Palermo 2
Palestrina 2
Palombara Sabina 2
Pavia 2
Philadelphia 2
Policoro 2
Poolesville 2
Porto Alegre 2
Totale 1.038
Salva come PNG Salva come JPEG
Nome #
Characterization of non-driver mutations and identification of different outcomes and treatment strategies based on NGS results in myelofibrosis patients in different clinical stages 177
Clinical relevance of silent red blood cell autoantibodies. 120
Oral mucositis prevention in allogeneic hematopoietic stem cell transplantation with the photobyomodulation: A single center case series 104
Incidence and outcome of severe complications in patients with paroxysmal nocturnal hemoglobinuria: A real life scenario from a single center 30 years experience 83
ANTI-HLA DONOR SPECIFIC ANTIBODIES (DSA) IN THE TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS AND DESENSITIZATION STRATEGY. UNICENTRIC PERSPECTIVE STUDY 71
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab 70
A 35 year single center transplant experience in chronic myeloid leukemia 69
Immune-hematologic monitoring after allogeneic stem cell transplantation: unicentric prospective study on 104 patients. 58
null 56
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients 54
null 51
null 45
Therapeutic strategies in low and high-risk MDS: What does the future have to offer? 44
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation 39
Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease 37
null 28
null 27
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) 27
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia. is it time to introduce it in the clinical practice? 27
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience 24
null 23
The advantages and risks of ruxolitinib for the treatment of polycythemia vera 23
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort 23
null 22
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients 20
Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS 20
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab 19
null 18
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases 18
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 18
One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission 16
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up 16
null 16
Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice 15
Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia 14
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience 14
Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort 13
null 11
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up 11
Pre‐exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents 10
null 10
null 10
The advantages and risks of ruxolitinib for the treatment of polycythemia vera 9
null 9
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice? 8
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group 8
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 8
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 8
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents 8
Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia 8
Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation 7
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study 7
null 5
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients 5
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort 1
Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS 1
Totale 1.663
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.216
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.216
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020118 0 0 0 0 0 10 44 18 12 21 11 2
2020/2021123 8 2 1 4 11 58 3 5 5 8 5 13
2021/2022255 2 4 5 12 46 13 1 14 44 19 62 33
2022/2023321 45 32 14 30 42 32 5 26 38 12 34 11
2023/2024380 28 26 37 24 46 34 17 22 9 54 25 58
2024/2025395 50 47 44 111 80 63 0 0 0 0 0 0
Totale 1.663